Drug intelligence / Profile preview

JY017

Development stage: Phase 1
Lead developer: Zhejiang Orient Gene Biotech
Modality: Antibody-Based Therapeutics

Overview

JY017 is a drug candidate currently in preclinical development by Beijing Oriental Biotech Co., Ltd. (also known as Beijing Dongfang Baitai Biotechnology Co., Ltd.) for the treatment of autoimmune diseases. While the specific mechanism of action has not been publicly disclosed, the developing company specializes in the research and development of biologics, including monoclonal antibodies, humanized monoclonal antibodies, bispecific antibodies, and antibody fusion proteins. Therefore, JY017 is likely a biologic, potentially an antibody-based therapy, aimed at modulating immune responses implicated in autoimmune conditions.

Other names: CD123+CLL-1 dual-target CAR-T cellsCD123/CLL-1 CAR-T

Targets

CLEC12AIL3RA (Interleukin 3 Receptor)

Beyond the preview

Go deeper on JY017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY017.

Explore the full profile